MOLN

MOLN

USD

Molecular Partners AG American Depositary Shares

$3.910-0.200 (-4.868%)

リアルタイム価格

Healthcare
バイオテクノロジー
スイス

価格チャート

Loading Chart...

主要指標

市場指標
企業ファンダメンタルズ
取引統計

市場指標

始値

$4.110

高値

$4.265

安値

$3.720

出来高

0.01M

企業ファンダメンタルズ

時価総額

146.2M

業種

バイオテクノロジー

Switzerland

取引統計

平均出来高

0.00M

取引所

NMS

通貨

USD

52週レンジ

安値 $3.36現在値 $3.910高値 $6.24

関連ニュース

GlobeNewswire

Molecular Partners presents additional preclinical proof-of-concept data on logic-gated CD3 Switch-DARPin at SITC 2025

Poster presentation outlines potential of CD3 Switch-DARPin T cell engager (TCE) using an AND-gate to overcome limitations of other TCEs Demonstrated selective T cell cytotoxicity against cells co-expressing

もっと見る
Molecular Partners presents additional preclinical proof-of-concept data on logic-gated CD3 Switch-DARPin at SITC 2025
GlobeNewswire

Molecular Partners to present updated data from Phase 1/2a trial of MP0533 in AML at ASH Annual Meeting

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company

もっと見る
Molecular Partners to present updated data from Phase 1/2a trial of MP0533 in AML at ASH Annual Meeting
GlobeNewswire

Molecular Partners Reports Q3 2025 Financial Results and Clinical Progress, with DLL3-Targeting Radio-DARPin MP0712 Phase 1 Launch Expected in 2025

IND application filed for MP0712, the Company's lead Radio-DARPin candidate targeting DLL3 and co-developed with Orano Med, with Phase 1 initiation expected before year end 2025 First patient images from MP0712

もっと見る
Molecular Partners Reports Q3 2025 Financial Results and Clinical Progress, with DLL3-Targeting Radio-DARPin MP0712 Phase 1 Launch Expected in 2025